Sunshine Biopharma (NASDAQ:SBFM) vs. Genocea Biosciences (NASDAQ:GNCA) Head-To-Head Analysis

Sunshine Biopharma (NASDAQ:SBFM) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Sunshine Biopharma and Genocea Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1	1	1	0	2.00
Genocea Biosciences	0	0	0	0	0.00

Sunshine Biopharma currently has a consensus target price of $70.00, indicating a potential upside of 5,882.91%. Given Sunshine Biopharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Sunshine Biopharma is more favorable than Genocea Biosciences.

Insider & Institutional Ownership

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Sunshine Biopharma and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Genocea Biosciences	N/A	-182.88%	-62.76%

Risk & Volatility

Sunshine Biopharma has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sunshine Biopharma and Genocea Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31 million	0.02	-$5.97 million	($10.15)	-0.12
Genocea Biosciences	$1.91 million	0.00	-$33.20 million	($0.61)	N/A

Sunshine Biopharma has higher revenue and earnings than Genocea Biosciences. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Sunshine Biopharma beats Genocea Biosciences on 8 of the 13 factors compared between the two stocks.

About Sunshine Biopharma

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.